Dolutegravir‐induced acquired sideroblastic anemia in a HIV positive patient: A challenging hematologic complication

Key Clinical Message Dolutegravir, the most recent antiretroviral drug with high efficacy, good tolerability, infrequent drug–drug interactions, and a favorable safety profile has not been reported in current literature as a cause of acquired sideroblastic anemia. Here, we present a 35‐year‐old male...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Kiran Dhonju, Ashmita Gautam, Abhinav Dahal, Niraj Kumar Sharma, Divas Adhikari, Lina Devkota, Prabhat Adhikari, Sampurna Tuladhar, Bishnu Deep Pathak, Sabin Banmala
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Wiley 2023-12-01
سلاسل:	Clinical Case Reports
الموضوعات:	acquired sideroblastic anemia adverse drug reaction Dolutegravir HIV Naranjo scale
الوصول للمادة أونلاين:	https://doi.org/10.1002/ccr3.8301
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!